Lipid Mediators in Health and Disease
A Tribute to Bengt Samuelsson

PROGRAM


Wednesday, August 27

11.30-13.00 Lunch

13.00-13.10 Welcome address
Jesper Z. Haeggström

13.10-14.00 Key Note Lecture
Bengt Samuelsson

Session 1: Phospholipases A₂
Chairpersons:

14.00-14.30 PLA₂, structures, mechanisms and membrane interactions
Edward A. Dennis

14.30-15.00 Roles of cPLA₂ in disease
Takao Shimizu

15.00-15.30 Novel biological functions of PLA₂
Makoto Murakami

15.30-15.50 Coffee break
Session 2: *Cyclooxygenases and prostanoid receptors*

Chairpersons:

15.50-16.20  COX-1 and COX-2  
*William L. Smith*

16.20-16.50  Prostanoid receptors  
*Shuh Narumiya*

Thursday, August 28

Session 3: *NSAIDs, from aspirin to coxibs and beyond.*

Chairpersons:

09.00-09.30  Pharmacology of aspirin and other NSAIDs  
*Carlo Patrono*

09.30-10.00  Eicosanoids in cardiovascular disease  
*Garret A. Fitzgerald*

10.00-10.30  Novel COX products and therapeutic opportunities  
*Lawrence J. Marnett*

10.30-10.50  *Coffee break*

Session 4: *Structures and sources of oxylipins.*

10.50-11.20  Mass spectrometry of oxylipins, past, present, and future  
*Robert C. Murphy*

11.20-11.50  Esterified oxylipins  
*Valerie B. O'Donnell*

11.50-13.00  *Lunch*

Session 5: *Lipoxygenases and leukotrienes*

Chairpersons:

13.00-13.30  5-lipoxygenase  
*Colin D. Funk*
13.30-14.00  Receptors for leukotriene B₄  
Takehiko Yokomizo

14.00-14.30  Cysteinyl-leukotrienes, enzymes and novel receptors  
K. Frank Austen

14.30-15.00  Anti-leukotrienes in the clinical management of asthma  
Sven-Erik Dahlén

15.00-15.30  Coffee break

15.30-16.00  12R- lipoxygenase, a key role in human ischtyosis  
Alan R. Brash

16.30-17.00  Enzymes in the leukotriene cascade, novel therapeutic opportunities  
Jesper Z. Haeggström

Friday, August 29

Session 4: Novel mediators in resolution of inflammation
Chairpersons:
09.00-09.25  Omega-3 fatty acids and synthesis of proresolving mediators  
Charles N. Serhan

09.25-09.50  Proresolving lipid mediators in asthma  
Bruce Levy

09.50-10.15  Resolvins for treatment of dry eye  
Per Gjorstrup

10.15-10.40  Lipid signaling for vision and neuroprotection  
Nicolas G. Bazan

10.40-11.00  Coffee break
**Session 5: Sphingolipids, from inborn neurodegenerative disorders to inflammation**

*Chairpersons:*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00-11.30</td>
<td>Discovery and bioactions of sphingosine-1-phosphate</td>
<td>Sarah Spiegel</td>
</tr>
<tr>
<td>11.30-12.00</td>
<td>Sphingosine kinases</td>
<td>Lina M. Obeid</td>
</tr>
<tr>
<td>12.00-13.00</td>
<td><em>Lunch</em></td>
<td></td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>Receptors for sphingosine-1-phosphate</td>
<td>Timothy Hla</td>
</tr>
<tr>
<td>13.30-14.00</td>
<td>Animal models for sphingolipid deficiency</td>
<td>Richard L. Proia</td>
</tr>
<tr>
<td>14.00-14.30</td>
<td>Fingolimod, a first line drug for treatment of MS</td>
<td>Volker Brinkmann</td>
</tr>
</tbody>
</table>

*Concluding remarks: Jesper Z. Haeggström, Tim Hla, Charles N. Serhan, Takao Shimizu*